Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Partnered Programs<br />
Phase 2 Clinical Development<br />
Program Partner Disease Target Status<br />
CNTO888<br />
CNTO888<br />
CNTO1959<br />
Janssen<br />
Biotech<br />
Janssen<br />
Biotech<br />
Janssen<br />
Biotech<br />
Oncology<br />
Idiopathic<br />
pulmonary<br />
fibrosis<br />
CCL2<br />
(MCP-1)<br />
CCL2<br />
(MCP-1)<br />
Two trials ongoing, one trial completed<br />
Novel approach to IPF<br />
Psoriasis IL23p19 Phase 2 trial started in December 2011<br />
n.d. Novartis n.d. n.d. Clinical proof of concept achieved<br />
n.d. Novartis Ophthalmology n.d. Phase 2 trial started in January 2012<br />
BHQ880 Novartis<br />
Osteolytic bone<br />
disease<br />
DKK-1<br />
Early data show stimulation of bone<br />
formation<br />
BYM338 Novartis Musculoskeletal n.d. Two phase 2 trials ongoing<br />
Gantenerumab Roche<br />
Alzheimer‘s<br />
disease<br />
Amyloid-b<br />
Only anti-Aβ antibody being developed<br />
in patients with prodromal AD<br />
© <strong>MorphoSys</strong> AG<br />
Page 26
Change language